Literature DB >> 24099915

MicroRNA-31 inhibits cisplatin-induced apoptosis in non-small cell lung cancer cells by regulating the drug transporter ABCB9.

Zhuo Dong1, Zhiwei Zhong1, Lihua Yang1, Shaomin Wang2, Zhaohui Gong3.   

Abstract

Alterations in microRNA (miRNA) expression have been found to be involved in tumor growth and response to chemotherapy. However, the possible role of miR-31 in cisplatin (DDP) resistance in non-small cell lung cancer (NSCLC) remains unclear. In this study, we identified a DDP-sensitive and a DDP-resistant cell line from four candidate human NSCLC cell lines. Notably, we found that miR-31 was significantly upregulated in the DDP-resistant cell line compared with its level in the DDP-sensitive cell line. As a result, miR-31 overexpression induced DDP resistance in the DDP-sensitive cell line, and miR-31 knockdown rescued DDP sensitivity in the DDP-resistant cell line. Interestingly, miR-31 was inversely correlated with the expression of the drug resistance gene ABCB9. The luciferase activity assay showed that miR-31 directly targets the 3'UTR of ABCB9, which is known to play a crucial role in drug resistance. Mechanistically, we showed that miR-31 confers DDP-induced apoptosis and that inhibition of ABCB9 is required for DDP resistance. The data demonstrate that miR-31 exerts an anti-apoptotic effect most likely through the inhibition of ABCB9 and thus provide a novel strategy involving the use of miR-31 as a potential target in NSCLC chemotherapy.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  ABCB9; Apoptosis; Cisplatin resistance; Non-small cell lung cancer; miR-31

Mesh:

Substances:

Year:  2013        PMID: 24099915     DOI: 10.1016/j.canlet.2013.09.034

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  53 in total

Review 1.  MicroRNA Pharmacoepigenetics: Posttranscriptional Regulation Mechanisms behind Variable Drug Disposition and Strategy to Develop More Effective Therapy.

Authors:  Ai-Ming Yu; Ye Tian; Mei-Juan Tu; Pui Yan Ho; Joseph L Jilek
Journal:  Drug Metab Dispos       Date:  2015-11-13       Impact factor: 3.922

Review 2.  Epigenetics of lung cancer.

Authors:  Scott M Langevin; Robert A Kratzke; Karl T Kelsey
Journal:  Transl Res       Date:  2014-03-12       Impact factor: 7.012

3.  A three-microRNA signature predicts responses to platinum-based doublet chemotherapy in patients with lung adenocarcinoma.

Authors:  Motonobu Saito; Kouya Shiraishi; Kenji Matsumoto; Aaron J Schetter; Hiroko Ogata-Kawata; Naoto Tsuchiya; Hideo Kunitoh; Hiroshi Nokihara; Shun-Ichi Watanabe; Koji Tsuta; Kensuke Kumamoto; Seiichi Takenoshita; Jun Yokota; Curtis C Harris; Takashi Kohno
Journal:  Clin Cancer Res       Date:  2014-08-20       Impact factor: 12.531

Review 4.  Function and regulation of microRNA-31 in development and disease.

Authors:  Nadezda A Stepicheva; Jia L Song
Journal:  Mol Reprod Dev       Date:  2016-08-02       Impact factor: 2.609

5.  PFKL/miR-128 axis regulates glycolysis by inhibiting AKT phosphorylation and predicts poor survival in lung cancer.

Authors:  Jie Yang; Jingqiu Li; Yanping Le; Chengwei Zhou; Shun Zhang; Zhaohui Gong
Journal:  Am J Cancer Res       Date:  2016-01-15       Impact factor: 6.166

6.  MiRNA signature predicts the response of patients with advanced lung adenocarcinoma to platinum-based treatment.

Authors:  Xiaoyue Xu; Shaorong Yu; Wenbo Sun; Xiaobing Qin; Yan Chen; Leilei Zhou; Rui Lou; Shuchen Dong; Bo Shen; Jianzhong Wu; Jialan Zang; Haixia Cao; Meiqi Shi; Qin Zhang; Jifeng Feng
Journal:  J Cancer Res Clin Oncol       Date:  2017-12-29       Impact factor: 4.553

7.  Therapeutic Inhibition of the Receptor Tyrosine Kinase AXL Improves Sensitivity to Platinum and Taxane in Ovarian Cancer.

Authors:  Jeanne M Quinn; Molly M Greenwade; Marguerite L Palisoul; Gregory Opara; Katina Massad; Lei Guo; Peinan Zhao; Hollie Beck-Noia; Ian S Hagemann; Andrea R Hagemann; Carolyn K McCourt; Premal H Thaker; Matthew A Powell; David G Mutch; Katherine C Fuh
Journal:  Mol Cancer Ther       Date:  2018-11-26       Impact factor: 6.261

8.  Detection of microRNA-200b may predict the inhibitory effect of gefitinib on non-small cell lung cancer and its potential mechanism.

Authors:  Zhiwu Liu; Liqiong Yao; Bangyun Tan; Li Li; Baojin Chen
Journal:  Oncol Lett       Date:  2016-11-08       Impact factor: 2.967

9.  Prognostic role of microRNA-31 in various cancers: a meta-analysis.

Authors:  Shuwei Wang; Jun Hu; Dongsheng Zhang; Juan Li; Qiang Fei; Yueming Sun
Journal:  Tumour Biol       Date:  2014-08-20

10.  Upregulated microRNA-224 promotes ovarian cancer cell proliferation by targeting KLLN.

Authors:  Ke Hu; Meng Liang
Journal:  In Vitro Cell Dev Biol Anim       Date:  2016-09-23       Impact factor: 2.416

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.